Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alcohol Drinking | 18 | 2017 | 4028 | 2.580 |
Why?
|
Alcoholic Beverages | 6 | 2016 | 264 | 1.710 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2022 | 269 | 1.240 |
Why?
|
Alcohol-Related Disorders | 4 | 2015 | 238 | 1.090 |
Why?
|
Australia | 13 | 2017 | 1250 | 1.000 |
Why?
|
Drug Users | 3 | 2014 | 134 | 0.970 |
Why?
|
Leisure Activities | 4 | 2017 | 308 | 0.960 |
Why?
|
Harm Reduction | 3 | 2015 | 144 | 0.820 |
Why?
|
Splenic Neoplasms | 1 | 2021 | 94 | 0.720 |
Why?
|
Automobile Driving | 2 | 2016 | 441 | 0.700 |
Why?
|
Food Industry | 2 | 2011 | 67 | 0.690 |
Why?
|
Self Efficacy | 2 | 2014 | 638 | 0.680 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2021 | 178 | 0.660 |
Why?
|
Cities | 3 | 2017 | 546 | 0.660 |
Why?
|
Risk-Taking | 3 | 2014 | 1038 | 0.620 |
Why?
|
Hematopoiesis | 7 | 2023 | 2049 | 0.610 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2023 | 2917 | 0.610 |
Why?
|
Sports | 3 | 2013 | 705 | 0.600 |
Why?
|
Violence | 2 | 2015 | 936 | 0.600 |
Why?
|
Adolescent Behavior | 3 | 2015 | 1190 | 0.570 |
Why?
|
Leukemia | 4 | 2022 | 1522 | 0.560 |
Why?
|
Crime | 2 | 2014 | 202 | 0.510 |
Why?
|
Alcoholic Intoxication | 2 | 2016 | 174 | 0.510 |
Why?
|
Licensure | 1 | 2016 | 128 | 0.500 |
Why?
|
Conflict of Interest | 2 | 2011 | 554 | 0.500 |
Why?
|
Juvenile Delinquency | 1 | 2015 | 117 | 0.490 |
Why?
|
DNA Damage | 2 | 2023 | 2446 | 0.470 |
Why?
|
Marketing | 3 | 2012 | 220 | 0.460 |
Why?
|
Internet | 4 | 2014 | 3092 | 0.460 |
Why?
|
Ascorbic Acid | 1 | 2017 | 655 | 0.460 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1374 | 0.450 |
Why?
|
Aggression | 3 | 2013 | 750 | 0.450 |
Why?
|
Industry | 2 | 2012 | 364 | 0.430 |
Why?
|
Mutation | 12 | 2024 | 30052 | 0.430 |
Why?
|
Substance Abuse Detection | 1 | 2015 | 301 | 0.420 |
Why?
|
Integrin beta3 | 1 | 2013 | 120 | 0.420 |
Why?
|
Food Labeling | 1 | 2015 | 179 | 0.420 |
Why?
|
Public Relations | 1 | 2011 | 22 | 0.390 |
Why?
|
Substance-Related Disorders | 5 | 2017 | 4420 | 0.390 |
Why?
|
Lymphoma | 1 | 2021 | 1901 | 0.380 |
Why?
|
Awareness | 1 | 2015 | 648 | 0.370 |
Why?
|
Neoplastic Stem Cells | 5 | 2018 | 1347 | 0.370 |
Why?
|
Wine | 1 | 2011 | 166 | 0.360 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 3204 | 0.360 |
Why?
|
Beer | 1 | 2010 | 134 | 0.340 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 1640 | 0.330 |
Why?
|
Personal Satisfaction | 1 | 2014 | 644 | 0.330 |
Why?
|
Dioxygenases | 2 | 2022 | 345 | 0.330 |
Why?
|
Breast Neoplasms | 4 | 2024 | 21012 | 0.320 |
Why?
|
Health Status | 2 | 2014 | 4077 | 0.320 |
Why?
|
Health Education | 1 | 2015 | 1052 | 0.310 |
Why?
|
Social Responsibility | 1 | 2011 | 386 | 0.310 |
Why?
|
Rural Population | 3 | 2014 | 2285 | 0.310 |
Why?
|
Universities | 2 | 2012 | 993 | 0.300 |
Why?
|
Athletes | 2 | 2012 | 1137 | 0.300 |
Why?
|
Financial Management | 1 | 2009 | 160 | 0.290 |
Why?
|
RNA Interference | 3 | 2016 | 2831 | 0.290 |
Why?
|
Data Collection | 3 | 2014 | 3322 | 0.290 |
Why?
|
Groin | 1 | 2007 | 106 | 0.290 |
Why?
|
Leukemia, Myeloid, Acute | 5 | 2019 | 3613 | 0.290 |
Why?
|
Behavior, Addictive | 2 | 2011 | 462 | 0.280 |
Why?
|
Femoral Vein | 1 | 2007 | 153 | 0.280 |
Why?
|
Wounds and Injuries | 2 | 2017 | 2491 | 0.270 |
Why?
|
Humans | 60 | 2024 | 761504 | 0.260 |
Why?
|
Social Behavior | 1 | 2012 | 1135 | 0.260 |
Why?
|
Urban Population | 1 | 2014 | 2036 | 0.260 |
Why?
|
Thalidomide | 2 | 2022 | 885 | 0.250 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1336 | 0.240 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 5315 | 0.230 |
Why?
|
Health Surveys | 2 | 2014 | 4061 | 0.220 |
Why?
|
Substance Abuse, Intravenous | 1 | 2007 | 529 | 0.210 |
Why?
|
Peptide Termination Factors | 1 | 2022 | 56 | 0.200 |
Why?
|
Allosteric Site | 1 | 2022 | 103 | 0.200 |
Why?
|
Oncogenes | 2 | 2022 | 1222 | 0.200 |
Why?
|
Hematopoietic Stem Cells | 6 | 2022 | 3396 | 0.200 |
Why?
|
Adenocarcinoma | 1 | 2019 | 6346 | 0.200 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2023 | 412 | 0.190 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2022 | 306 | 0.180 |
Why?
|
Female | 27 | 2024 | 392644 | 0.180 |
Why?
|
Dipeptides | 1 | 2022 | 391 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 191 | 0.170 |
Why?
|
Polymerization | 1 | 2020 | 158 | 0.170 |
Why?
|
Quality of Life | 2 | 2014 | 13367 | 0.170 |
Why?
|
Hematologic Neoplasms | 3 | 2022 | 1896 | 0.170 |
Why?
|
Young Adult | 12 | 2022 | 59243 | 0.170 |
Why?
|
Toll-Like Receptor 9 | 1 | 2020 | 233 | 0.170 |
Why?
|
Taxes | 2 | 2011 | 221 | 0.160 |
Why?
|
Mice | 13 | 2023 | 81525 | 0.160 |
Why?
|
Adult | 18 | 2024 | 221177 | 0.160 |
Why?
|
Ferritins | 1 | 2022 | 598 | 0.160 |
Why?
|
Patient-Centered Care | 1 | 2009 | 1421 | 0.160 |
Why?
|
Sampling Studies | 2 | 2010 | 615 | 0.160 |
Why?
|
Serine | 1 | 2022 | 830 | 0.150 |
Why?
|
Aminopyridines | 1 | 2022 | 573 | 0.150 |
Why?
|
Cell Cycle | 2 | 2023 | 2932 | 0.150 |
Why?
|
N-Methyl-3,4-methylenedioxyamphetamine | 2 | 2010 | 65 | 0.150 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13380 | 0.150 |
Why?
|
Adolescent | 11 | 2022 | 88319 | 0.150 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2023 | 515 | 0.150 |
Why?
|
Mice, Mutant Strains | 1 | 2020 | 1749 | 0.150 |
Why?
|
Male | 22 | 2022 | 360804 | 0.140 |
Why?
|
Health Policy | 1 | 2010 | 2684 | 0.140 |
Why?
|
Victoria | 2 | 2014 | 64 | 0.140 |
Why?
|
Odds Ratio | 2 | 2022 | 9646 | 0.140 |
Why?
|
Public Policy | 2 | 2011 | 559 | 0.140 |
Why?
|
Structure-Activity Relationship | 1 | 2022 | 3076 | 0.140 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2023 | 1897 | 0.130 |
Why?
|
Middle Aged | 14 | 2024 | 220895 | 0.130 |
Why?
|
Germ Cells | 1 | 2020 | 634 | 0.130 |
Why?
|
CLOCK Proteins | 1 | 2016 | 86 | 0.130 |
Why?
|
ARNTL Transcription Factors | 1 | 2016 | 96 | 0.130 |
Why?
|
Neoplasms | 2 | 2022 | 22170 | 0.130 |
Why?
|
Gout | 1 | 2022 | 621 | 0.120 |
Why?
|
Age Factors | 3 | 2016 | 18395 | 0.120 |
Why?
|
Self Report | 2 | 2017 | 3724 | 0.120 |
Why?
|
Base Sequence | 2 | 2018 | 12441 | 0.120 |
Why?
|
Selection, Genetic | 1 | 2019 | 868 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1052 | 0.120 |
Why?
|
Protein Conformation | 1 | 2022 | 3968 | 0.120 |
Why?
|
Research Design | 1 | 2010 | 6180 | 0.120 |
Why?
|
Animals | 14 | 2023 | 168459 | 0.120 |
Why?
|
Casein Kinase Ialpha | 1 | 2014 | 26 | 0.120 |
Why?
|
Social Control, Formal | 1 | 2014 | 108 | 0.120 |
Why?
|
Sequence Deletion | 1 | 2018 | 1494 | 0.110 |
Why?
|
Health Personnel | 1 | 2007 | 3335 | 0.110 |
Why?
|
Age of Onset | 1 | 2020 | 3305 | 0.110 |
Why?
|
Biomedical Research | 1 | 2009 | 3429 | 0.110 |
Why?
|
Aged | 9 | 2024 | 169289 | 0.110 |
Why?
|
Principal Component Analysis | 1 | 2016 | 943 | 0.110 |
Why?
|
Markov Chains | 1 | 2016 | 966 | 0.100 |
Why?
|
Signal Transduction | 2 | 2013 | 23445 | 0.100 |
Why?
|
Alcoholism | 2 | 2016 | 1973 | 0.100 |
Why?
|
Databases, Genetic | 1 | 2019 | 1742 | 0.100 |
Why?
|
Myeloproliferative Disorders | 1 | 2018 | 613 | 0.100 |
Why?
|
Ethics, Business | 1 | 2011 | 8 | 0.100 |
Why?
|
Sex Distribution | 1 | 2017 | 2281 | 0.100 |
Why?
|
Immunotherapy, Adoptive | 1 | 2021 | 1469 | 0.100 |
Why?
|
Chromatin | 1 | 2023 | 2960 | 0.100 |
Why?
|
Peer Review, Research | 1 | 2014 | 340 | 0.090 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2013 | 718 | 0.090 |
Why?
|
Logistic Models | 2 | 2016 | 13255 | 0.090 |
Why?
|
Age Distribution | 1 | 2017 | 2880 | 0.090 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1258 | 0.090 |
Why?
|
Antisocial Personality Disorder | 1 | 2011 | 224 | 0.090 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2013 | 305 | 0.090 |
Why?
|
Central Nervous System Depressants | 1 | 2011 | 164 | 0.090 |
Why?
|
Databases, Bibliographic | 1 | 2010 | 130 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2019 | 2571 | 0.090 |
Why?
|
Interviews as Topic | 1 | 2017 | 2696 | 0.080 |
Why?
|
Mental Recall | 1 | 2015 | 1214 | 0.080 |
Why?
|
Vitamins | 1 | 2017 | 1635 | 0.080 |
Why?
|
Risk Factors | 4 | 2022 | 74206 | 0.080 |
Why?
|
Heroin Dependence | 1 | 2009 | 172 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4511 | 0.080 |
Why?
|
Program Development | 1 | 2014 | 1297 | 0.080 |
Why?
|
beta Catenin | 1 | 2013 | 1040 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9280 | 0.070 |
Why?
|
RNA, Small Interfering | 2 | 2016 | 3429 | 0.070 |
Why?
|
Enzyme Inhibitors | 1 | 2018 | 3712 | 0.070 |
Why?
|
Employment | 1 | 2014 | 1118 | 0.070 |
Why?
|
Cell Death | 3 | 2022 | 1678 | 0.070 |
Why?
|
DNA-Binding Proteins | 2 | 2022 | 9606 | 0.070 |
Why?
|
Research Support as Topic | 1 | 2011 | 697 | 0.070 |
Why?
|
Genetic Enhancement | 1 | 2006 | 17 | 0.070 |
Why?
|
Glioma | 1 | 2022 | 3455 | 0.070 |
Why?
|
Genomics | 2 | 2019 | 5821 | 0.070 |
Why?
|
Neuraminidase | 1 | 2006 | 196 | 0.070 |
Why?
|
Linear Models | 1 | 2016 | 5871 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3617 | 0.070 |
Why?
|
Program Evaluation | 1 | 2014 | 2495 | 0.070 |
Why?
|
N-Acetylneuraminic Acid | 1 | 2006 | 174 | 0.060 |
Why?
|
Commerce | 1 | 2011 | 606 | 0.060 |
Why?
|
Cross-Sectional Studies | 3 | 2017 | 26125 | 0.060 |
Why?
|
Injections, Intravenous | 1 | 2007 | 1379 | 0.060 |
Why?
|
Personal Autonomy | 1 | 2007 | 304 | 0.060 |
Why?
|
Social Environment | 1 | 2010 | 1020 | 0.060 |
Why?
|
Ligands | 2 | 2023 | 3272 | 0.060 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2013 | 1606 | 0.060 |
Why?
|
Smoking | 1 | 2022 | 9053 | 0.060 |
Why?
|
Ethanol | 1 | 2011 | 1324 | 0.060 |
Why?
|
Prospective Studies | 3 | 2024 | 54425 | 0.060 |
Why?
|
Hedgehog Proteins | 1 | 2009 | 768 | 0.060 |
Why?
|
Stem Cells | 1 | 2017 | 3522 | 0.060 |
Why?
|
Prevalence | 2 | 2024 | 15732 | 0.060 |
Why?
|
Mice, Inbred C57BL | 4 | 2019 | 22169 | 0.060 |
Why?
|
Transcription Factors | 1 | 2023 | 12128 | 0.060 |
Why?
|
Immunotherapy | 1 | 2019 | 4652 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5305 | 0.050 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2023 | 189 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7827 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12059 | 0.050 |
Why?
|
Mice, Knockout | 2 | 2019 | 14414 | 0.050 |
Why?
|
Sex Factors | 1 | 2016 | 10552 | 0.050 |
Why?
|
Demography | 1 | 2007 | 1648 | 0.050 |
Why?
|
Ubiquitins | 1 | 2023 | 366 | 0.050 |
Why?
|
Choice Behavior | 1 | 2007 | 824 | 0.050 |
Why?
|
Research | 1 | 2010 | 1982 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4811 | 0.050 |
Why?
|
Pilot Projects | 2 | 2022 | 8631 | 0.050 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17635 | 0.040 |
Why?
|
Genes, p53 | 1 | 2022 | 712 | 0.040 |
Why?
|
Brain Stem Neoplasms | 1 | 2022 | 190 | 0.040 |
Why?
|
Solvents | 1 | 2020 | 295 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 368 | 0.040 |
Why?
|
Mental Health | 1 | 2014 | 3250 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 794 | 0.040 |
Why?
|
Adenosine Triphosphatases | 1 | 2023 | 835 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2015 | 14605 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 857 | 0.040 |
Why?
|
Glycoproteins | 1 | 2006 | 2203 | 0.040 |
Why?
|
Synthetic Biology | 1 | 2020 | 185 | 0.040 |
Why?
|
Patient Selection | 1 | 2010 | 4244 | 0.040 |
Why?
|
Cell Line, Tumor | 4 | 2018 | 16981 | 0.040 |
Why?
|
Public Health | 1 | 2011 | 2669 | 0.040 |
Why?
|
K562 Cells | 1 | 2019 | 642 | 0.040 |
Why?
|
Medical Record Linkage | 1 | 2019 | 285 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2007 | 1998 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2007 | 2319 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2023 | 80636 | 0.040 |
Why?
|
Inflammasomes | 1 | 2022 | 526 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2022 | 2218 | 0.030 |
Why?
|
Interleukin-1beta | 1 | 2022 | 999 | 0.030 |
Why?
|
Genes, Dominant | 1 | 2019 | 852 | 0.030 |
Why?
|
Cryoelectron Microscopy | 1 | 2020 | 650 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3461 | 0.030 |
Why?
|
Uric Acid | 1 | 2022 | 807 | 0.030 |
Why?
|
Health Behavior | 1 | 2007 | 2643 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2014 | 15842 | 0.030 |
Why?
|
Ubiquitination | 1 | 2020 | 1006 | 0.030 |
Why?
|
Substrate Specificity | 1 | 2019 | 1791 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1732 | 0.030 |
Why?
|
Time Factors | 1 | 2016 | 39967 | 0.030 |
Why?
|
DNA Repair | 1 | 2023 | 2045 | 0.030 |
Why?
|
Ribosomal Protein S6 | 1 | 2014 | 71 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1320 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2022 | 3514 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2007 | 3889 | 0.030 |
Why?
|
Lovastatin | 1 | 2013 | 115 | 0.030 |
Why?
|
Ontario | 1 | 2014 | 398 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2013 | 7879 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2016 | 802 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2007 | 4016 | 0.030 |
Why?
|
Tyrphostins | 1 | 2012 | 63 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2022 | 4278 | 0.030 |
Why?
|
Prognosis | 2 | 2024 | 29625 | 0.020 |
Why?
|
New South Wales | 1 | 2011 | 69 | 0.020 |
Why?
|
Blast Crisis | 1 | 2012 | 102 | 0.020 |
Why?
|
Incidence | 1 | 2010 | 21353 | 0.020 |
Why?
|
Benzothiazoles | 1 | 2012 | 247 | 0.020 |
Why?
|
Serpins | 1 | 2012 | 247 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13639 | 0.020 |
Why?
|
Models, Molecular | 1 | 2020 | 5439 | 0.020 |
Why?
|
Financial Support | 1 | 2011 | 117 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3802 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2007 | 5440 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2022 | 18252 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 651 | 0.020 |
Why?
|
Small Molecule Libraries | 1 | 2014 | 733 | 0.020 |
Why?
|
Child | 2 | 2022 | 80153 | 0.020 |
Why?
|
Survival Rate | 1 | 2022 | 12725 | 0.020 |
Why?
|
Obesity | 1 | 2010 | 12947 | 0.020 |
Why?
|
Gene Silencing | 1 | 2014 | 1509 | 0.020 |
Why?
|
Adult Stem Cells | 1 | 2009 | 221 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5796 | 0.020 |
Why?
|
Lung | 1 | 2023 | 10000 | 0.020 |
Why?
|
Cricetulus | 1 | 2006 | 814 | 0.010 |
Why?
|
Circadian Rhythm | 1 | 2016 | 2576 | 0.010 |
Why?
|
Genotype | 1 | 2019 | 12990 | 0.010 |
Why?
|
Neoplasms, Experimental | 1 | 2009 | 1229 | 0.010 |
Why?
|
CHO Cells | 1 | 2006 | 1387 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9420 | 0.010 |
Why?
|
Phosphorylation | 1 | 2014 | 8320 | 0.010 |
Why?
|
Cricetinae | 1 | 2006 | 2423 | 0.010 |
Why?
|
Protein Engineering | 1 | 2006 | 549 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5791 | 0.010 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2009 | 1250 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11742 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2022 | 39106 | 0.010 |
Why?
|
Infant | 1 | 2022 | 36192 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 42230 | 0.010 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3245 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2024 | 58976 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2014 | 5671 | 0.010 |
Why?
|
Databases, Factual | 1 | 2013 | 7967 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10445 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2014 | 64680 | 0.000 |
Why?
|